Drug
Adaplane 0.1%
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Skin Irritation | 483 | 43.0 | 47.3 | signal |
| 2 | Skin Burning Sensation | 491 | 28.1 | 30.9 | signal |
| 3 | Acne | 464 | 24.8 | 27.1 | signal |
| 4 | Dry Skin | 798 | 24.7 | 29.0 | signal |
| 5 | Therapy Cessation | 227 | 18.0 | 18.8 | signal |
| 6 | Pain Of Skin | 91 | 13.7 | 13.9 | signal |
| 7 | Skin Exfoliation | 271 | 13.2 | 13.9 | signal |
| 8 | Scar | 41 | 9.7 | 9.7 | signal |
| 9 | Erythema | 402 | 7.9 | 8.5 | signal |
| 10 | Drug Ineffective | 2,412 | 7.4 | 13.0 | signal |
| 11 | Skin Reaction | 25 | 7.2 | 7.2 | signal |
| 12 | Application Site Irritation | 20 | 6.5 | 6.5 | signal |
| 13 | Application Site Pain | 31 | 5.7 | 5.7 | signal |
| 14 | Dermatitis | 29 | 5.7 | 5.7 | signal |
| 15 | Condition Aggravated | 416 | 5.6 | 6.0 | signal |
| 16 | Therapeutic Response Decreased | 77 | 5.2 | 5.2 | signal |
| 17 | Application Site Erythema | 32 | 4.9 | 4.9 | signal |
| 18 | Therapeutic Product Effect Incomplete | 76 | 4.3 | 4.4 | signal |
| 19 | Skin Fissures | 20 | 4.3 | 4.3 | signal |
| 20 | Scab | 12 | 4.3 | 4.3 | signal |
| 21 | Hypersensitivity | 166 | 3.6 | 3.7 | signal |
| 22 | Therapeutic Response Unexpected | 40 | 3.6 | 3.6 | signal |
| 23 | Rash Macular | 27 | 3.1 | 3.1 | signal |
| 24 | Rash | 336 | 3.1 | 3.3 | signal |
| 25 | Application Site Rash | 10 | 2.9 | 2.9 | signal |
| 26 | Rash Maculo-papular | 16 | 2.9 | 2.9 | signal |
| 27 | Adverse Reaction | 9 | 2.7 | 2.7 | signal |
| 28 | Skin Haemorrhage | 9 | 2.5 | 2.5 | signal |
| 29 | Application Site Pruritus | 14 | 2.5 | 2.5 | signal |
| 30 | Swelling Face | 40 | 2.5 | 2.5 | signal |
| 31 | Rash Erythematous | 28 | 2.4 | 2.4 | signal |
| 32 | Folliculitis | 6 | 2.3 | 2.3 | no signal |
| 33 | Dermatitis Allergic | 7 | 2.3 | 2.3 | no signal |
| 34 | Drug Effective For Unapproved Indication | 16 | 2.2 | 2.2 | signal |
| 35 | Skin Discolouration | 25 | 2.2 | 2.2 | signal |
| 36 | Eye Swelling | 20 | 2.2 | 2.2 | signal |
| 37 | Burning Sensation | 35 | 2.0 | 2.0 | signal |
| 38 | Sleep Disorder Due To A General Medical Condition | 7 | 1.7 | 1.8 | no signal |
| 39 | Product Packaging Issue | 4 | 1.7 | 1.7 | no signal |
| 40 | Photosensitivity Reaction | 7 | 1.7 | 1.7 | no signal |
| 41 | Inappropriate Schedule Of Product Administration | 73 | 1.7 | 1.7 | no signal |
| 42 | Drug Effect Less Than Expected | 5 | 1.4 | 1.4 | no signal |
| 43 | Abortion Induced | 3 | 1.3 | 1.3 | no signal |
| 44 | Product Substitution Issue | 17 | 1.2 | 1.2 | no signal |
| 45 | Exposure During Pregnancy | 18 | 1.2 | 1.2 | no signal |
| 46 | Dermatitis Atopic | 14 | 1.1 | 1.1 | no signal |
| 47 | Bipolar Disorder | 3 | 1.1 | 1.1 | no signal |
| 48 | Eye Irritation | 15 | 1.1 | 1.1 | no signal |
| 49 | Expired Product Administered | 8 | 1.0 | 1.0 | no signal |
| 50 | Drug Dispensing Error | 3 | 0.8 | 0.8 | no signal |
| 51 | Multiple Fractures | 3 | 0.7 | 0.7 | no signal |